Entacapone vs Tolcapone — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Catechol-O-Methyltransferase Inhibitor

Entacapone

First FDA approval: 2013-04-01

Catechol-O-Methyltransferase Inhibitor

Tolcapone

Brand: Tasmar

First FDA approval: 2004-07-27

Lowest NADACAcquisition cost floor across all NDCs

$0.360Per unit

—Per unit

Average NADACAcross all dosage forms and strengths

$0.360Up to $0.360

—

Generic manufacturersActive ANDA holders — FDA Orange Book

77 total ANDAs filed

11 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$29.0MFull year

$689158Full year

Part D claims (CY24)Total fills, all strengths

198K48K beneficiaries

19035 beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$146Per claim, all NDCs

$3,627Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

4Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes7 manufacturers

Yes1 manufacturers